OrthoPediatrics Corp. (NASDAQ:KIDS) Stock Has Consensus Target Price of $30.75 According to Brokerages

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have earned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $30.75.

Several research firms recently commented on KIDS. Piper Sandler reiterated an “overweight” rating and issued a $30.00 price target (up from $25.00) on shares of OrthoPediatrics in a research report on Wednesday, October 28th. Truist Financial upped their price objective on OrthoPediatrics from $22.00 to $28.00 and gave the company a “hold” rating in a research report on Wednesday, October 28th. Lake Street Capital raised their price objective on OrthoPediatrics from $34.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OrthoPediatrics in a research note on Tuesday, November 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $35.00 target price on shares of OrthoPediatrics in a report on Wednesday, October 28th.

Insider Buying and Selling at OrthoPediatrics

In other news, major shareholder Jennifer N. Pritzker sold 302,369 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the transaction, the insider owned 6,201,764 shares in the company, valued at approximately $130,299,061.64. This trade represents a 4.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Squadron Capital Llc sold 302,369 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the transaction, the insider owned 6,201,764 shares in the company, valued at approximately $130,299,061.64. This represents a 4.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 2,100,000 shares of company stock valued at $46,747,931 in the last ninety days. Corporate insiders own 32.50% of the company’s stock.

Institutional Trading of OrthoPediatrics

A number of hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its holdings in shares of OrthoPediatrics by 70.3% in the 3rd quarter. GAMMA Investing LLC now owns 1,165 shares of the company’s stock valued at $26,000 after acquiring an additional 481 shares during the period. Legal & General Group Plc purchased a new stake in shares of OrthoPediatrics during the 2nd quarter worth $34,000. Quantinno Capital Management LP purchased a new stake in shares of OrthoPediatrics during the 1st quarter worth $160,000. Waverly Advisors LLC bought a new stake in OrthoPediatrics during the first quarter valued at about $184,000. Finally, Bank of America Corp DE bought a new stake in OrthoPediatrics during the second quarter valued at about $268,000. 69.05% of the stock is owned by hedge funds and other institutional investors.

OrthoPediatrics Price Performance

NASDAQ KIDS opened at $31.76 on Monday. The stock has a 50 day moving average price of $24.06 and a 200-day moving average price of $19.92. OrthoPediatrics has a one year low of $14.42 and a one year high of $34.53. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.00 and a current ratio of 4.55. The company has a market capitalization of $829.25 million, a P/E ratio of -22.21 and a beta of 0.90.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Tuesday, October 27th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.02). OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 12.83%. The business had revenue of $72.66 million during the quarter, compared to the consensus estimate of $68.50 million. As a group, equities analysts predict that OrthoPediatrics will post -1.09 EPS for the current fiscal year.

About OrthoPediatrics

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. The company designs implants, instruments and related technologies intended to address the distinct anatomical and clinical needs of pediatric patients, including those with congenital conditions, traumatic injuries and musculoskeletal disorders.

Its product portfolio covers pediatric trauma and deformity correction, scoliosis, limb reconstruction, sports medicine and other specialized orthopedic procedures.